Document is current
Any future updates will be listed below
-
Authors
Ziegler, Yvonne
Kumar, Sandeep
Saeh, Carlos M.
Plotner, Blake N.
Pento, Grace O.
Kim, Sung Hoon
Raghavan, Alekya
Schiff, Rachel
Katzenellenbogen, John A.
Katzenellenbogen, Benita S.
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-145)
Breast Cancer Research Foundation (BCRF-083)
Congressionally Directed Medical Research Programs (W81XWH02101-0610)
National Institutes of Health (1R01 CA220284)
- License Information
-
More Information
Article History
Received: 25 September 2025
Accepted: 31 January 2026
First Online: 12 February 2026
Competing interests
: B.S.K., J.A.K., and S.K. are co-inventors on a Provisional Application filed by the University of Illinois to cover the FOXM1 inhibitor compounds used herein. BSK declares that she is on the Scientific Advisory Board of Celcuity, Inc. B.S.K. receives research grant funding from the Breast Cancer Research Foundation and has received recent research grant funding from the NIH/NCI. JAK declares that he is on the Scientific Advisory Board of Celcuity, Inc. and that he receives research funding from Cadenza Biosciences. J.A.K. declares that he has also received recent research grant funding from the NIH/NCI. R.S. declares research funding/grants to her institution (past and present) from AstraZeneca, GlaxoSmithKline, Puma, Biotechnology Inc, and Gilead Sciences, speaker honoraria and/or travel expenses from Binaytara Foundation and Dava Oncology, LP, and advisory board fees from Eli Lilly Daiichi Sankyo (Ad hoc), and MacroGenics. She declares royalties from UpToDate, is co-inventor in the Baylor College of Medicine’s pending patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response), and has served as a member of the SABCS (San Antonio Breast Cancer Symposium) Faculty/Planning Committees. The other authors state they have no competing interests.
